

Mara Chaparro

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6833719/maria-chaparro-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189
papers

5,512
citations

39
h-index

67
g-index

245
ext. papers

6,868
ext. citations

3.9
avg, IF

5.88
L-index

#	Paper	IF	Citations
189	How to prepare a research proposal in the health sciences?. <i>Gastroenterología Y Hepatología</i> , 2021 , 44, 730-740	0.9	1
188	Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
187	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2021 ,	1.5	2
186	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2021 ,	1.5	19
185	The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	12
184	Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 1846-1851	1.5	3
183	Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease. <i>Microorganisms</i> , 2021 , 9,	4.9	21
182	Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience. <i>Scandinavian Journal of Gastroenterology</i> , 2021 , 56, 806-811	2.4	0
181	Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
180	Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal Tract. <i>Molecular Nutrition and Food Research</i> , 2021 , 65, e2001034	5.9	2
179	Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1277-1288	6.1	1
178	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
177	Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience. <i>United European Gastroenterology Journal</i> , 2021 , 9, 766	5.3	6
176	Profiling of Human Circulating Dendritic Cells and Monocyte Subsets Discriminates Between Type and Mucosal Status in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 268-274	4.5	1
175	Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 35-42	1.5	13
174	Tissue Proteomic Approaches to Understand the Pathogenesis of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1184-1200	4.5	0
173	Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4

172	Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
171	Challenges of independent clinical research. <i>Gastroenterología Y Hepatología</i> , 2021 , 44, 599-610	0.9	1
170	Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 144, 112239	7.5	3
169	The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211018097	4.7	2
168	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2021 ,	1.5	1
167	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 606-616	4.5	19
166	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	17
165	Errors in the care of inflammatory bowel disease patients: Errata Study. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020 , 43, 233-239	0.1	
164	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 588-596	2.2	2
163	Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. <i>Drugs</i> , 2020 , 80, 1085-1100	12.1	12
162	Endothelial MT1-MMP targeting limits intussusceptive angiogenesis and colitis via TSP1/nitric oxide axis. <i>EMBO Molecular Medicine</i> , 2020 , 12, e10862	12	21
161	Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 155-168	0.9	7
160	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 649-658	0.9	1
159	Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 1037-1048	1.5	30
158	Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020 , 43, 155-168	0.1	3
157	Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1802-1811	0.7	5
156	Survey of adherence to treatment in inflammatory bowel disease. ENADEII study. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 285-292	0.9	0
155	Quality of care through the eyes of the patient in a Spanish inflammatory bowel disease unit. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 688-693	0.9	0

154	Diagnosis and Outcome of Oesophageal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 624-629.	1.5	1
153	Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 694-709	1.5	54
152	Tips and guidelines for being a successful researcher. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 540-550.	0.9	3
151	Errors in the care of inflammatory bowel disease patients: "Errata" Study. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 233-239	0.9	
150	Response to the Letter to the Editor: "Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease". <i>Inflammatory Bowel Diseases</i> , 2020 , 26, e6	4.5	
149	Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 273-283	0.9	3
148	Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819867848	4.7	
147	Microbiota Sensing by Mincle-Syk Axis in Dendritic Cells Regulates Interleukin-17 and -22 Production and Promotes Intestinal Barrier Integrity. <i>Immunity</i> , 2019 , 50, 446-461.e9	32.3	87
146	Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: the Practicrohn study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 807-813	4.2	2
145	Epidemiology: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819847034	4.7	9
144	Role of food proteins and bioactive peptides in inflammatory bowel disease. <i>Trends in Food Science and Technology</i> , 2019 , 88, 194-206	15.3	31
143	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 568-578	0.9	5
142	Immunomodulatory Effect of Gut Microbiota-Derived Bioactive Peptides on Human Immune System from Healthy Controls and Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , 2019 , 11,	6.7	15
141	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial.. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819874202	4.7	0
140	'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 127-137	1.5	23
139	Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 846-854	4	15
138	Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 419-428	6.1	18
137	Peptides encrypted in the human intestinal microbial-exoproteome as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract. <i>Journal of Functional Foods</i> , 2019 , 52, 459-468	5.1	8

136	Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 374-384	1.5	20
135	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 205-221	0.1	2
134	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 205-221	0.9	23
133	Human Intestinal Dendritic Cells in Inflammatory Bowel Diseases. <i>Molecular Nutrition and Food Research</i> , 2018 , 62, e1700931	5.9	24
132	Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018 , 50, 353-359	3.3	19
131	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 112-127	0.9	13
130	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 514-529	0.9	23
129	Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1270-1279	1.5	12
128	Acute severe ulcerative colitis: State of the art treatment. <i>Baillieres's Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 32-33, 59-69	2.5	20
127	Human intestinal pro-inflammatory CD11cCCR2CX3CR1 macrophages, but not their tolerogenic CD11cCCR2CX3CR1 counterparts, are expanded in inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018 , 11, 1114-1126	9.2	56
126	Importance of endoscopist quality metrics for findings at surveillance colonoscopy: The detection-surveillance paradox. <i>United European Gastroenterology Journal</i> , 2018 , 6, 622-629	5.3	11
125	Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. <i>Scandinavian Journal of Gastroenterology</i> , 2018 , 53, 152-157	2.4	9
124	Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 839-851	6.1	53
123	Pregnancy and Inflammatory Bowel Disease: A Long Way to Go. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1903-1904	0.7	
122	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 514-529	0.1	1
121	The Innate Immune System in the Gastrointestinal Tract: Role of Intraepithelial Lymphocytes and Lamina Propria Innate Lymphoid Cells in Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1649-1659	4.5	28
120	Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 389-405	0.9	17
119	Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 389-405	0.1	1

118	Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1605-1613	4.5	21
117	Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1135-1143	0.7	15
116	Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 792-800	1.5	13
115	Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 481-490	4	31
114	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2017 , 112, 120-131	0.7	66
113	Ustekinumab to treat Crohn's disease. <i>Gastroenterología Y Hepatología</i> , 2017 , 40, 688-698	0.9	8
112	Ratio of Circulating Estrogen Receptors Beta and Alpha (ER β /ER α) Indicates Endoscopic Activity in Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 2744-2754	4	20
111	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease. <i>Gastroenterología Y Hepatología</i> , 2017 , 40, 472-483	0.9	18
110	Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 1430-1439	1.5	72
109	Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1709-1718	0.7	42
108	Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1394-1402	4.5	47
107	Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. <i>Journal of Gastroenterology</i> , 2017 , 52, 788-799	6.9	33
106	Ustekinumab to treat Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017 , 40, 688-698	0.1	
105	Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1662-9	4.5	113
104	Tu1925 Real-Life Experience With Golimumab in Ulcerative Colitis Patients According to Prior Anti-TNF Use. <i>Gastroenterology</i> , 2016 , 150, S979	13.3	2
103	Tu1990 Correlation Between Anti-TNF Serum Levels and Mucosal Healing (MH) in Inflammatory Bowel Disease (IBD) Patient. <i>Gastroenterology</i> , 2016 , 150, S999	13.3	3
102	Maintenance therapy options for ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1339-49	4	13
101	Effectiveness of anti-TNF α drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNF α agent. <i>Digestive and Liver Disease</i> , 2016 , 48, 613-9	3.3	9

100	Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 657-62	1.5	17
99	The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2016 , 111, 632-47	0.7	99
98	Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 1186-93	1.5	26
97	Endoscopist characteristics that influence the quality of colonoscopy. <i>Endoscopy</i> , 2016 , 48, 241-7	3.4	29
96	Actualizaci3n del diagn3stico y tratamiento de la enfermedad de Crohn. <i>Medicine</i> , 2016 , 12, 217-226	0.1	
95	Manifestaciones extraintestinales en la enfermedad inflamatoria intestinal. <i>Medicine</i> , 2016 , 12, 242-248	0.1	1
94	Protocolo de diagn3stico y tratamiento de la colitis ulcerosa grave corticorrefractaria. <i>Medicine</i> , 2016 , 12, 260-262	0.1	
93	Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2016 , 39, 255-60	0.9	3
92	High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. <i>Blood Transfusion</i> , 2016 , 14, 199-205	3.6	14
91	Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 894-901	4.5	55
90	Clinical Course of Bone Metabolism Disorders in Patients with Inflammatory Bowel Disease: A 5-Year Prospective Study. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1929-36	4.5	11
89	Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. <i>Biochemical Pharmacology</i> , 2016 , 122, 33-41	6	9
88	Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1020	6.1	
87	Treatment of inflammatory bowel disease: what's new in Digestive Disease Week 2016. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2016 , 39 Suppl 1, 20-28	0.9	
86	Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2016 , 39, 508-15	0.9	30
85	Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease. <i>Gastroenterolog3a Y Hepatolog3a (English Edition)</i> , 2016 , 39, 255-260	0.1	
84	New molecules in the treatment of inflammatory bowel disease. <i>Gastroenterolog3a Y Hepatolog3a (English Edition)</i> , 2016 , 39, 411-423	0.1	
83	Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 379-86	2.4	18

82	Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 613-23	6.1	184
81	Incidence, management, and course of cancer in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 326-33	1.5	23
80	Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy. <i>Journal of Clinical Gastroenterology</i> , 2015 , 49, 34-40	3	46
79	Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 3075-84	4	21
78	Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 1302-3	6.1	
77	Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 847-58.e4; quiz e48-50	6.9	246
76	Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 940-1	6.1	1
75	Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 391-405	6.1	68
74	Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease. <i>World Journal of Gastroenterology</i> , 2015 , 21, 2260-2	5.6	10
73	Effect of Chondroitin Sulphate on Pro-Inflammatory Mediators and Disease Activity in Patients with Inflammatory Bowel Disease. <i>Digestion</i> , 2015 , 92, 203-10	3.6	9
72	Identification of risk loci for Crohn's disease phenotypes using a genome-wide association study. <i>Gastroenterology</i> , 2015 , 148, 794-805	13.3	39
71	Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11273-81	5.6	35
70	Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 1529-38	1.5	28
69	How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 1749-62	4.1	10
68	A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. <i>Human Molecular Genetics</i> , 2014 , 23, 6927-34	5.6	31
67	Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 183-90	1.5	24
66	Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 120-1	6.1	1
65	Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 645-59	6.1	169

64	Systematic review with meta-analysis: inflammatory bowel disease in the elderly. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 459-77	6.1	105
63	The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 695-702	4.5	15
62	Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease. <i>Current Drug Metabolism</i> , 2014 , 15, 875-81	3.5	2
61	Antimetabolite Therapy in Ulcerative Colitis: Azathioprine, 6-Mercaptopurine, and Methotrexate 2014 , 135-143		
60	How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study. <i>Digestive and Liver Disease</i> , 2013 , 45, 733-7	3.3	11
59	Health care costs of complex perianal fistula in Crohn's disease. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 3400-6	4	24
58	Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, e569-79	1.5	21
57	Reply to Dr. Katsanos et al.'s letter. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, e23-4	1.5	
56	Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, e61-5	1.5	2
55	Vaccination strategies in patients with IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013 , 10, 277-85	24.2	22
54	Letter: measurement of anti-TNF levels and antibodies against the drug. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 163-4	6.1	0
53	Safety of thiopurines and anti-TNF drugs during pregnancy in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2013 , 108, 433-40	0.7	157
52	New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients. <i>Pharmacogenomics</i> , 2013 , 14, 631-40	2.6	16
51	Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. <i>Gastrointestinal Endoscopy</i> , 2013 , 77, 381-389.e1	5.2	97
50	Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1426-38	0.7	88
49	Should we monitor vitamin B12 and folate levels in Crohn's disease patients?. <i>Scandinavian Journal of Gastroenterology</i> , 2013 , 48, 1272-7	2.4	45
48	Letter: dry blood spots for anti-TNF treatment monitoring in IBD--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 1025-6	6.1	1
47	Response to Tung et al. <i>American Journal of Gastroenterology</i> , 2013 , 108, 621-2	0.7	

46	Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 554-8	4.5	30
45	Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 1404-10	4.5	190
44	Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1379-85	6.1	62
43	Letter: mucosal PCR for cytomegalovirus in refractory ulcerative colitis Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 812-812	6.1	
42	Sa1903 Effectiveness and Safety of Ustekinumab as Rescue Therapy in Multi-Drug Resistant Crohn's Disease. <i>Gastroenterology</i> , 2012 , 142, S-355	13.3	4
41	Systematic review: antibodies and anti-TNF levels in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 971-86	6.1	72
40	Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1460-6	0.7	98
39	Intensification of infliximab therapy in Crohn's disease: efficacy and safety. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 62-7	1.5	32
38	Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 518-23	1.5	65
37	Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 950-3	1.5	10
36	Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 1034-7	1.5	16
35	Long-term durability of response to adalimumab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 685-90	4.5	43
34	Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn's disease: are antibiotics enough?. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1509-14	4.5	44
33	Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 2026-33	4.5	100
32	Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 275-83	6.1	83
31	Validation of a genotyping method for analysis of TPMT polymorphisms. <i>Clinical Therapeutics</i> , 2012 , 34, 878-84	3.5	8
30	Effectiveness of infliximab after adalimumab failure in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5219-24	5.6	22
29	Demographic Difference of Hepatosplenic T-Cell Lymphoma (HSTCL) Versus Non-HSTCL Lymphoma in Patients with IBD Receiving Thiopurines: A Population Cohort Analysis. <i>American Journal of Gastroenterology</i> , 2012 , 107, S632	0.7	2

28	Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 397-401	1.5	21
27	Overall Incidence of Hepatosplenic T Cell Lymphoma in Patients With Inflammatory Bowel Disease on Thiopurines: A Meta-Analysis of Three Population Based Studies. <i>Gastroenterology</i> , 2011 , 140, S-775	13.3	3
26	Comparative Study to Evaluate the Effectiveness of Two Different Vaccination Protocols Against Hepatitis B Virus (HBV) in Inflammatory Bowel Disease (IBD) Patients. <i>Gastroenterology</i> , 2011 , 140, S-587-588 ³	13.3	3
25	Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , 2011 , 34, 385-92	0.9	22
24	Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience. <i>Gastroenterología Y Hepatología</i> , 2011 , 34, 443-8	0.9	22
23	Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 113-8	3	97
22	Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011 , 36, 695-703	2.2	1
21	Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 340-8	6.1	76
20	Influenza A (H1N1)v infection in patients with inflammatory bowel disease: a case series. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 499-500	6.1	11
19	Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 125-45	6.1	390
18	Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 619-33	6.1	87
17	Successful use of infliximab for perianal Crohn's disease in pregnancy. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 868-9	4.5	9
16	Clinical patterns and outcomes of ischaemic colitis: results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE study). <i>Scandinavian Journal of Gastroenterology</i> , 2011 , 46, 236-46	2.4	108
15	Epidemiological Study of Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2011 , 140, S-736	13.3	4
14	H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. <i>Gut</i> , 2011 , 60, 456-62	19.2	60
13	Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease. <i>Current Drug Metabolism</i> , 2011 , 12, 594-8	3.5	18
12	Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. <i>Current Pharmaceutical Biotechnology</i> , 2011 , 12, 765-73	2.6	32
11	Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. <i>World Journal of Gastroenterology</i> , 2011 , 17, 493-8	5.6	19

10	Prospective evaluation of a clinical guideline recommending early patients discharge in bleeding peptic ulcer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 1525-9	4	4
9	Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. <i>Journal of Oncology</i> , 2010 , 2010, 272170	4.5	39
8	Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. <i>Gut</i> , 2010 , 59, 1340-6	19.2	136
7	Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 629-36	1.5	22
6	Accuracy of computed tomographic colonography for the detection of polyps and colorectal tumors: a systematic review and meta-analysis. <i>Digestion</i> , 2009 , 80, 1-17	3.6	61
5	Azathioprine plus ribavirin treatment and pancytopenia. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 962-3	6.1	9
4	Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 1269-77	6.1	51
3	Computed tomography colonography compared with conventional colonoscopy for the detection of colorectal polyps. <i>Gastroenterología Y Hepatología</i> , 2007 , 30, 375-80	0.9	7
2	Mechanisms of angiogenesis in chronic inflammatory liver disease. <i>Annals of Hepatology</i> , 2007 , 6, 208-213	3.1	32
1	Mechanisms of angiogenesis in chronic inflammatory liver disease. <i>Annals of Hepatology</i> , 2007 , 6, 208-13	3.1	21